Viatris Inc. Class Action Lawsuit - VTRS

According to the complaint, defendants provided investors with material information concerning the failed inspection of Viatris’ Indore, India facility. Defendants’ statements misrepresented the FDA’s issuance of a warning letter and its impact on Viatris' operations. Defendants routinely referred to the impact of the warning letter as a mere “minor headwind” for the Company. On February 27, 2025, Viatris announced its financial results for the fourth quarter and full fiscal year 2024 and provided disappointing fiscal 2025 guidance. The Company attributed below-expectation guidance on “the expected financial impact from Indore facility warning letter and import alert.” Following this news, the price of Viatris’ common stock declined dramatically. From a closing market price of $11.24 per share on February 26, 2025, Viatris’ stock price fell to $9.53 per share on February 27, 2025, a decline of about 15.21% in the span of just a single day.

In order to be eligible to join the VTRS class action lawsuit, you must have incurred a loss on shares of Viatris purchased during the class period listed above.

If you suffered a loss in Viatris during the relevant time frame or pursuant to the relevant offering(s), you have until June 3, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.